<DOC>
	<DOC>NCT00418704</DOC>
	<brief_summary>The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.</brief_summary>
	<brief_title>Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>A multicenter phase II trial , prospective, randomized, open, non comparative</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; 65 years Comorbidities score, PS frailty score**.according to(TABLE N°1) No dementia, repeated falls, faecal or urinary incontinence, ADL=0, IADL=0 Life expectancy at least 12 weeks Créatinine clearance de la créatinine &gt; or =30cc/mn according to Cockrofts Gault formula Competency to give written informed consent Haematological function as follows: absolute neutrophil count &gt; 1.5 x 109/l and/or platelet&gt; 100 x 109/l, hémoglobine &gt; or = 9,5 g/dl Hepatic function as followed :bilirubin &lt;1,25 LNS SGOT/SGPT &lt;5 x N,PAL &lt;5N PS &lt; 3 No symptomatic cerebral metastasis Histologically or cytologically confirmed NSCLC Stage IV/IIIB4 (T4with pleural effusion) No prior chemotherapy for NSCLC Relapses of previous NSCLC treated by surgery or radiotherapy are eligible if the target is measurable out of initial radiotherapy field and if histological or cytological proof At least one measurable target lesion by RECIST guidelines. Symptomatic cerebral metastasis Any severe comorbidity calculated by Charlson score (according to table 1), any kind of disorder that compromises the ability of the subject to give written informed and/or comply with the study procedure ADL &gt; or = 1 et IADL &gt; or =1 Dementia, repeated falls, faecal or urinary incontinence Peripheral neuropathy grade 2 or more Performance Status &gt; 2 ( ECOG) Contraindication to corticosteroids Unwilling or unable to comply with study requirements for personal , family, sociologic, geographic or any reasons Lack of liberty following administrative or judicial decision Hypersensitivity to polysorbate Hypersensitivity to erlotinib or any excipients of this product Unusual hereditary disorders as galactosemia, deficit in lactase and malabsorption in glucose or galactose Participation in concomitant clinical trial Contraindication to a product of this study disease Bronchioloalvéolar or neuroendocrine or composite carcinoma Superior vena cava syndrome</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>None small-cell lung cancer</keyword>
</DOC>